InnoCan Pharma Corporation
INNPD
$12.53
-$0.39-3.02%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -10.13% | 44.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -10.13% | 44.34% | |||
| Cost of Revenue | 19.09% | -31.35% | |||
| Gross Profit | -12.93% | 61.37% | |||
| SG&A Expenses | -12.77% | 28.79% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.54% | 15.62% | |||
| Operating Income | -19.02% | 153.21% | |||
| Income Before Tax | -430.30% | 1,000.00% | |||
| Income Tax Expenses | -21.37% | 413.73% | |||
| Earnings from Continuing Operations | -37.55% | -377.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 22.10% | -434.85% | |||
| Net Income | -1.37% | -410.53% | |||
| EBIT | -19.02% | 153.21% | |||
| EBITDA | -18.84% | 154.65% | |||
| EPS Basic | -0.69% | -405.04% | |||
| Normalized Basic EPS | 14.65% | -413.10% | |||
| EPS Diluted | -0.69% | -405.04% | |||
| Normalized Diluted EPS | 14.65% | -413.10% | |||
| Average Basic Shares Outstanding | 0.66% | 1.15% | |||
| Average Diluted Shares Outstanding | 0.66% | 1.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||